Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Catalyst Pharmaceuticals, Inc.

< Previous 1 2 Next >
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers CPRX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS